الصفحة 2
الصفحة 2
Biophysical Aspects of Transmembrane Signaling
Transmembrane signaling is one of the most significant cell biological events in the life and death of cells in general and lymphocytes in particular. Until recently biochemists and biophysicists were not accustomed to thinking of these processes from the side of a high number of complex biochemical events and an equally high number of physical changes at molecular and cellular levels at the same time. Both types of researchers were convinced that their findings are the most decisive, having higher importance than the findings of the other scientist population. Both casts were wrong. Life, even at cellular level, has a number of interacting physical and biochemical mechanisms, which finally build up the creation of an "excited" cell that will respond to particular signals from the outer or inner world.
Atlas effectors of anti-tumor immunity
The “Atlas Effectors of Anti-Tumor Immunity” is a unique scientific publication, which includes major issues of up-to-date information about immunophenotype, morphology and function of main effectors of anti-tumor immunity presented in a reasonable format. The Atlas comprises a large number of illustrations presented by schemes and original micrographs demonstrating morphological features and ultrastructure of immunocompetent cells at various stages of differentiation. The volume includes data referring to the history of anti-tumor immunity effectors research, state of the art and perspectives for development of anti-cancer adoptive immunotherapy methods.A special section of the Atlas describes cellular tumor microenvironment and micro-anatomy of carcinomas. Several parts include data about killer cells (natural killer T-cells, lymphokine-activated killers) and T-regulatory lymphocytes. A special chapter gives a wide-range description of antigen-presenting dendritic cells, methods of dendritic cell generation and development of DC-based vaccines for anti-tumor immunotherapy.
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
Covers all aspects of Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV). The expression refers to a group of diseases, characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, lung, skin, nervous system and others. presents recently acquired knowledge on pathogenesis, diagnosis, and therapy with the aim of promoting a more holistic approach to these conditions. AAVs are systemic autoimmune diseases of unknown cause that affect small (to medium) sized blood vessels. They include granulomatosis with polyangiitis (formerly Wegener's granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome).
Angiogenesis in Inflammation : Mechanisms and Clinical Correlates
This volume relates the lessons learned from tumour biology applied to inflammation. This issue of Angiogenesis in Inflammation: Mechanisms and Clinical Correlates develops current knowledge on the mechanisms at the molecular and cellular levels as they relate to inflammation, including acute and chronic inflammation, neurogenic initiation, and the role of the multiple cellular components that comprise inflammation: granulocytes, macrophages, fibroblasts, dendritic cells and lymphocytes. This is related to inflammatory disease: not only the familiar angiogenesis dependent diseases of rheumatoid arthritis and psoriasis, but also loci such as the lung, gastric ulcers, the eye with uveitis, wound healing and periodontal disease and their therapy, how this knowledge may be used in the discovery of novel therapeutics. The volume brings together experts in each of these fields to link the molecular and cellular processes in angiogenesis to those of inflammation and disease, culminating in a discourse on areas for future therapies.
Analyzing T cell responses : How to analyze cellular immune responses against tumor associated antigens
Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer
